The eye in systemic inflammatory diseases

Lancet

Volumn 364, Issue 9451, 2004, Pages 2125-2133

  McCluskey, Peter ^a,c   Powell, Prof Richard J ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGE DISTRIBUTION; AORTA ARCH SYNDROME; BEHCET DISEASE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; CORNEA TRANSPLANTATION; DIFFERENTIAL DIAGNOSIS; EPISCLERITIS; GIANT CELL ARTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; KERATITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEOPLASM; POLYARTERITIS NODOSA; PRIORITY JOURNAL; RELAPSING POLYCHONDRITIS; RETINA VASCULITIS; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERITIS; SEX ROLE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS; VOGT KOYANAGI SYNDROME; WEGENER GRANULOMATOSIS;

EID: 10344227163     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17554-5     Document Type: Conference Paper

References (45)

1. Fong LP, Sainz de la Maza M, Rice BA, Foster CS. Immunopathology of scleritis. Ophthalmol. 98:1991;472-477
2. Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 43:1999;379-396
3. Watts RA, Scott DGI. Classification and epidemiology of the vasculitides. Bailliere's Clin Rheumatol. 11:1997;191-217
4. Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum. 24:1981;899-904
5. Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 110:2003;539-542
6. Allison MC, Gallagher PJ. Temporal artery biopsy and corticosteroid treatment. Ann Rheum Dis. 43:1984;416-417
7. Andersson R, Malmvall BE, Bengtsson BA. Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study of 90 patients treated with corticosteroids. Acta Med Scand. 220:1986;361-364
8. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med. 100:1996;193-196
9. Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy proven giant cell arteritis. Ophthalmology. 110:2003;539-542
10. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 41:1998;1497-1504
11. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant cell arteritis with methotrexate and prednisolone. A randomised double-blind, placebo-controlled trial. Ann Intern Med. 134:2001;106-114
12. Cantini F, Niccoli L, Salvarini C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 44:2001;2933-2935
13. Hall S, Barr W, Lie JT, et al. Takayasu arteritis. A study of 32 North American patients. Medicine. 64:1985;88-99
14. Ishikawa K. Natural history and classification of occlusive thromboaortopathy (Takayasu's disease). Circulation. 57:1978;27-35
15. Jabs DA. Rheumatic diseases. Ryan SJ. Retina. 1994;1437 Mosby, St Louis, MO
16. Shelhamer JH, Volkman DJ, Parrilo JE, et al. Takayasu's arteritis and its therapy. Ann Intern Med. 103:1985;121-126
17. Valskumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol. 30:2003;1793-1798
18. Foster CS, Sainz de la Maza M. The sclera. 1994;209-211 New York, Springer-Verlag
19. Shulman ST, De Inocencio J, Hirsch R. Kawasaki disease. Paediatr Clin North Am. 42:1995;1205-1222
20. Shingalia D, Bose A, Booy R. Could a herpesvirus be the cause of Kawasaki Disease? Lancet Infect Dis. 2:2002;310-313
21. Williams RV, Minich LL, Tani LY. Pharmacological therapy for patients with Kawasaki disease. Paediatr Drugs. 3:2001;649-660
22. Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation. 75:1987;387-394
23. Weiner J, Cupples H, Zimmerman LE. Granulomatous diseases of the ocular adnexa. Otolaryngol Clin N Amer. 15:1982;519-528
24. Watson PG. The nature and treatment of scleral inflammation. Trans Ophthalmol Soc. 102:1982;257-264
25. Harman LE, Margo CE. Wegener's granulomatosis. Surv Ophthalmol. 42:1998;458-480
26. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotising scleritis or peripheral ulcerative keratitis: effects of systemic immunosuppression. Ophthalmology. 9:1984;1253-1263
27. Watson PG. McCluskey PJ. Scleritis. 2001;24 BMJ Books, London
28. Taylor. PC. Anti-TNF α therapy for rheumatoid arthritis: an update. Intern Med. 42:2003;15-20
29. Morton SJ, Powell RJ. Management of systemic lupus erythematosus. Clin Exp Allerg. 31:2001;686-693
30. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and the lacrimal gland. Cornea. 17:1998;584-649
31. International Study Group for Behçets Disease. Criteria for diagnosis of Behçets disease. Lancet. 335:1990;1078-1080
32. Chavis PS, Tabbara KF. Behçet's disease. Int Ophthalmol Clin. 25:1995;43-67
33. Muhaya M, Lightman S, Ikeda E, et al. Behçet's Disease in Japan and Britain: a comparative study. Ocul Immunol Inflammat. 8:2000;141-148
34. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçets syndrome. N Engl J Med. 322:1997;281-285
35. Humuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçets syndrome, arthritis, and rheumatism, 1997; 40: 760-74.
36. Diaz-Llopis M, Cervera M, Menezo JL. Cyclosporin A treatment of Behçet's disease: a long -term study. Curr Eye Res. 9:1990;17-23
37. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçets disease. Lancet. 358:2001;295-296
38. Zeuner M, Straub RH, Rauh G, et al. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol. 24:1997;96-101
39. Jones NP. Sarcoidosis and uveitis. Ophthalmol Clin North Am. 15:2002;319-326
40. Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. 84:2000;110-116
41. Edelsten C, Pearson A, Joynes E, Stanford MR, Graham EM. The ocular and systemic prognosis of patients presenting with sarcoid uveitis. Eye. 13:1999;748-753
42. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 39:1995;265-292
43. Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 131:2001;599-606
44. Okhravi N, Lightman SL, Towler HMA. Assessment of visual outcome in patients after cataract surgery in patients with uveitis. Ophthalmol. 106:1999;710-722
45. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 109:2002;1377-1382